53.81
price up icon0.28%   0.15
after-market Handel nachbörslich: 53.74 -0.07 -0.13%
loading
Schlusskurs vom Vortag:
$53.66
Offen:
$53.71
24-Stunden-Volumen:
2.23M
Relative Volume:
1.22
Marktkapitalisierung:
$4.30B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-269.44M
KGV:
-14.35
EPS:
-3.75
Netto-Cashflow:
$-262.63M
1W Leistung:
+16.98%
1M Leistung:
+23.82%
6M Leistung:
+43.11%
1J Leistung:
+79.31%
1-Tages-Spanne:
Value
$53.66
$53.98
1-Wochen-Bereich:
Value
$45.91
$54.53
52-Wochen-Spanne:
Value
$21.34
$58.40

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name
Firmenname
Akero Therapeutics Inc
Name
Telefon
650-487-6488
Name
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
67
Name
Twitter
@akerotx
Name
Nächster Verdiensttermin
2025-08-08
Name
Neueste SEC-Einreichungen
Name
AKRO's Discussions on Twitter

Vergleichen Sie AKRO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AKRO
Akero Therapeutics Inc
53.81 4.30B 0 -269.44M -262.63M -3.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
412.22 104.45B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
469.36 60.95B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.60 59.11B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.95 49.23B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.94 35.92B 4.56B -176.77M 225.30M -1.7177

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-09-04 Fortgesetzt H.C. Wainwright Buy
2025-08-04 Eingeleitet TD Cowen Buy
2025-01-30 Hochstufung BofA Securities Neutral → Buy
2025-01-27 Bestätigt H.C. Wainwright Buy
2024-11-18 Eingeleitet Citigroup Buy
2024-04-22 Fortgesetzt BofA Securities Neutral
2023-09-19 Eingeleitet Cantor Fitzgerald Overweight
2023-08-28 Eingeleitet UBS Buy
2023-01-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-09-14 Hochstufung Evercore ISI In-line → Outperform
2021-10-19 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-09-10 Eingeleitet BofA Securities Buy
2021-02-26 Eingeleitet Guggenheim Buy
2020-09-10 Eingeleitet Morgan Stanley Overweight
2020-07-20 Bestätigt H.C. Wainwright Buy
2020-07-07 Eingeleitet Chardan Capital Markets Buy
2020-07-01 Bestätigt H.C. Wainwright Buy
2020-03-02 Eingeleitet H.C. Wainwright Buy
2020-02-10 Eingeleitet Canaccord Genuity Buy
2019-07-15 Eingeleitet Evercore ISI Outperform
2019-07-15 Eingeleitet JP Morgan Overweight
2019-07-15 Eingeleitet Jefferies Buy
2019-07-15 Eingeleitet ROTH Capital Buy
Alle ansehen

Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten

pulisher
06:23 AM

Will Akero Therapeutics Inc. stock gain from lower inflationQuarterly Profit Review & AI Based Buy and Sell Signals - newser.com

06:23 AM
pulisher
05:19 AM

Is Akero Therapeutics Inc. forming a bottoming baseJuly 2025 WrapUp & Long-Term Safe Return Strategies - newser.com

05:19 AM
pulisher
02:46 AM

Will Akero Therapeutics Inc. stock reach Wall Street targetsQuarterly Market Summary & Safe Capital Allocation Plans - newser.com

02:46 AM
pulisher
Oct 13, 2025

StockWatch: Novo Nordisk Raises MASH Bet with Up-to-$5.2B Akero Acquisition - Genetic Engineering and Biotechnology News

Oct 13, 2025
pulisher
Oct 13, 2025

Novo Nordisk to Acquire Akero Therapeutics for $4.7B - Contract Pharma

Oct 13, 2025
pulisher
Oct 13, 2025

Is Akero Therapeutics Inc. stock bottoming outWeekly Investment Report & Verified Stock Trade Ideas - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

TD Cowen Downgrades Akero Therapeutics to Hold From Buy, Adjusts Price Target to $58 From $76 - MarketScreener

Oct 13, 2025
pulisher
Oct 13, 2025

Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring a 20% Upside Potential in Biotech - DirectorsTalk Interviews

Oct 13, 2025
pulisher
Oct 13, 2025

Is Akero Therapeutics Inc. stock a buy before product launchesQuarterly Trade Summary & Fast Entry Momentum Trade Alerts - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Custom watchlist performance reports with Akero Therapeutics Inc.July 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Novo Nordisk to acquire Akero Therapeutics for up to USD 5.2 billion - Medical Dialogues

Oct 13, 2025
pulisher
Oct 12, 2025

Real time breakdown of Akero Therapeutics Inc. stock performanceMarket Activity Summary & Daily Momentum Trading Reports - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

Novo Nordisk to acquire Akero Therapeutics for $5.2 billion - Indian Pharma Post

Oct 12, 2025
pulisher
Oct 12, 2025

The week in pharma: action, reaction and insight – week to October 10 - The Pharma Letter

Oct 12, 2025
pulisher
Oct 11, 2025

Akero Therapeutics (NASDAQ:AKRO) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Akero Therapeutics' (AKRO) Peer Perform Rating Reiterated at Wolfe Research - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Akero Therapeutics (NASDAQ:AKRO) Cut to "Neutral" at HC Wainwright - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Lifesci Capital Downgrades Akero Therapeutics (NASDAQ:AKRO) to Hold - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Akero Therapeutics (NASDAQ:AKRO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat

Oct 11, 2025
pulisher
Oct 10, 2025

Akero Therapeutics (NASDAQ:AKRO) Insider Sells $576,000.00 in Stock - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc.AKRO - Business Wire

Oct 10, 2025
pulisher
Oct 10, 2025

Akero Therapeutics (NASDAQ:AKRO) Shares Gap UpShould You Buy? - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An - GlobeNewswire

Oct 10, 2025
pulisher
Oct 10, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO) - GlobeNewswire Inc.

Oct 10, 2025
pulisher
Oct 10, 2025

Akero Therapeutics Acquired by Novo Nordisk for $5.2B - The Globe and Mail

Oct 10, 2025
pulisher
Oct 10, 2025

Akero Therapeutics (NASDAQ:AKRO) Cut to Hold at Jefferies Financial Group - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Akero Therapeutics (NASDAQ:AKRO) Downgraded by Canaccord Genuity Group to Hold - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Quantitative breakdown of Akero Therapeutics Inc. recent moveWeekly Profit Report & Free Low Drawdown Momentum Trade Ideas - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - Yahoo Finance

Oct 10, 2025
pulisher
Oct 10, 2025

This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga

Oct 10, 2025
pulisher
Oct 10, 2025

How to recover losses in Akero Therapeutics Inc. stockJuly 2025 Intraday Action & Weekly Chart Analysis and Trade Guides - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Novo Nordisk: New CEO Executing on Focused Strategy With Akero Acquisition - Morningstar Canada

Oct 10, 2025
pulisher
Oct 10, 2025

Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance? - Zacks Investment Research

Oct 10, 2025
pulisher
Oct 10, 2025

Wolfe Research Downgrades Akero Therapeutics (AKRO) to Peer Perf - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

Wolfe Research Downgrades Akero Therapeutics to Peer Perform From Outperform - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

HC Wainwright Downgrades Akero Therapeutics to Neutral From Buy, $72 Price Target - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

Novo makes bold $5.2bn bet on MASH treatment with Akero buy - BioXconomy

Oct 10, 2025
pulisher
Oct 10, 2025

Akero: Novo Nordisk Acquisition Puts Focus On Unprecedented MASH Data With EFX (AKRO) - Seeking Alpha

Oct 10, 2025
pulisher
Oct 10, 2025

Akero says new owner Novo Nordisk to drive commercialisation process - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

Novo Nordisk analyst on Akero acquisition: Buys potentially best remedy for fatty liver - medwatch.com

Oct 10, 2025
pulisher
Oct 10, 2025

Novo Nordisk to expand MASH portfolio with $5.2 Bn Akero Therapeutics buyout - ET Pharma

Oct 10, 2025
pulisher
Oct 10, 2025

What drives Akero Therapeutics Inc 0K4 stock priceDividend Stability Analysis & Stocks With 200% Upside Potential - earlytimes.in

Oct 10, 2025
pulisher
Oct 10, 2025

Is Akero Therapeutics Inc. (0K4) stock included in top ETFsBull Run & Verified Stock Trade Ideas - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Akero Therapeutics Inc. stock momentum explainedJuly 2025 Action & Momentum Based Trading Ideas - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk Merger - MSN

Oct 09, 2025
pulisher
Oct 09, 2025

Key facts: Novo Nordisk to Acquire Akero for $5.2 Billion; R&D Costs to Rise - TradingView

Oct 09, 2025
pulisher
Oct 09, 2025

Novo Nordisk to Acquire Akero Therapeutics for $5.2B, Targeting Breakthrough Liver Drug - Azat TV

Oct 09, 2025
pulisher
Oct 09, 2025

Akero Therapeutics Inc. (AKRO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Oct 09, 2025
pulisher
Oct 09, 2025

Akero therapeutics CSO sells $576k in shares - Investing.com

Oct 09, 2025
pulisher
Oct 09, 2025

Akero Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:AKRO - Benzinga

Oct 09, 2025
pulisher
Oct 09, 2025

Novo Nordisk to acquire clinical-stage drugmaker Akero Therapeutics - MLex

Oct 09, 2025

Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.75
price down icon 5.15%
$85.96
price up icon 1.45%
$32.75
price up icon 0.21%
$102.61
price up icon 0.30%
$161.38
price down icon 1.56%
biotechnology ONC
$320.94
price down icon 1.86%
Kapitalisierung:     |  Volumen (24h):